The specific populations studied were selected based on expected intrinsic high tumor expression of AXL (e.g., sarcoma) or hypothesized increased AXL tumor expression upon development of drug resistance in prior lines of therapy (e.g., relapsed/refractory NSCLC and melanoma). This evidence concerns the gene AXL and sarcoma.